Head and neck carcinoma in the United States: First comprehensive report of the Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN)

Cancer

Volumn 118, Issue 23, 2012, Pages 5783-5792

  Ang, K Kian ^a   Chen, Amy ^b,c   Curran Jr , Walter J ^c   Garden, Adam S ^a   Harari, Paul M ^d   Murphy, Barbara A ^e   Wong, Stuart J ^f   Bellm, Lisa A ^g   Schwartz, Marc ^g   Newman, Jason ^h   Adkins, Douglas ⁱ   Hayes, D Neil ^j   Parvathaneni, Upendra ^k   Brachman, David ^l   Ghabach, Bassam ^m   Schneider, Charles J ⁿ   Greenberg, Michael ^o   Anné, Pramila R ^p  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMERICAN CANCER SOCIETY   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g MedNet Solutions   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ WASHINGTON UNIVERSITY   (United States)

^j UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^l Arizona Oncology Services   (United States)

^m UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

ⁿ CHRISTIANA CARE HEALTH SYSTEM   (United States)

^o Pocono Medical Center   (United States)

^p THOMAS JEFFERSON UNIVERSITY   (United States)

more..

Author keywords

chemoradiation; head and neck cancer; outcomes; registry; supportive care

Indexed keywords

AMIFOSTINE; ANTIEMETIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; OPIATE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; LARYNX CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; NASOPHARYNX CANCER; OBSERVATIONAL STUDY; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT RESPONSE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; CLINICAL TRIALS AS TOPIC; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REGISTRIES; UNITED STATES;

EID: 84869490978     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27609     Document Type: Article

References (14)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society; 2010.
2. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute [based on November 2009 SEER data submission, posted to the SEER web site, 2010]. Bethesda, MD: 2010. Available at: http://seer.cancer.gov/csr/1975-2007/. [Accessed April 19, 2012.]
3. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16: 1310-1317. (Pubitemid 28175745)
4. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998; 338: 1798-1804. (Pubitemid 28277960)
5. Adelstein DJ, Li Y, Adams GL, et al. An Intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.
6. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349: 2091-2098. (Pubitemid 37464533)
7. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004; 22: 4665-4673.
8. Pignon JP, Bourhis J, Domenge C, Designe L,. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. Lancet. 2000; 355: 949-955. (Pubitemid 30148259)
9. Pignon JP, le Maitre A, Maillard E, Bourhis J,; MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92: 4-14.
10. Bonner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354: 567-578. (Pubitemid 43209104)
11. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357: 1705-1715. (Pubitemid 350005152)
12. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007; 357: 1695-1704. (Pubitemid 350005151)
13. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009; 101: 498-506.
14. Bonner J, Harari P, Giralt J, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab [abstract]. J Clin Oncol. 2004; 22: 14S. Abstract 5507.